Efficacy and Safety of Golimumab as Add-on Therapy to Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Results of the GO-MORE Study in Spain

Statistics

Original Article

Eficacia y seguridad de golimumab añadido a fármacos antirreumáticos modificadores de la enfermedad en artritis reumatoide. Resultados del estudio GO-MORE en España

Alberto Alonsoa, Carlos M. Gonzálezb, Javier Ballinac, María L. García Vivard, Juan J. Gómez-Reinoe, Jose Luis Marencof, Antonio Fernández-Nebrog, Carmen Ordásh, Luis Cea-Calvoi,

Corresponding author

luis.cea@merck.com

Corresponding author.

, María J. Arteagai, Raimon Sanmartíj

a Departamento de Reumatología, Hospital de Cruces, Barakaldo, Vizcaya, Spain

b Departamento de Reumatología, Hospital Universitario Gregorio Marañón, Madrid, Spain

c Departamento de Reumatología, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain

d Departamento de Reumatología, Hospital Universitario de Basurto, Bilbao, Vizcaya, Spain

e Departamento de Reumatología, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain

f Departamento de Reumatología, Hospital Universitario de Valme, Sevilla, Spain

g Departamento de Reumatología, Hospital Regional Carlos Haya, Universidad de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain

h Departamento de Reumatología, Hospital de Cabueñes, Gijón, Asturias, Spain

i Departamento de Medical Affairs, Merck Sharp & Dohme de Spain, Spain

j Hospital Clínic i Provincial, Barcelona, Spain

Read

5663

Times
was read the article

2112

Total PDF

3551

Total HTML

Share statistics

Article information

ISSN: 21735743
Original language: English

DOI:10.1016/j.reumae.2014.05.002

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 April	31	17	48
2024 March	53	37	90
2024 February	25	18	43
2024 January	35	26	61
2023 December	17	37	54
2023 November	30	32	62
2023 October	37	30	67
2023 September	79	36	115
2023 August	48	17	65
2023 July	32	27	59
2023 June	32	32	64
2023 May	43	21	64
2023 April	18	9	27
2023 March	60	34	94
2023 February	64	29	93
2023 January	31	16	47
2022 December	72	41	113
2022 November	61	37	98
2022 October	59	33	92
2022 September	32	39	71
2022 August	29	32	61
2022 July	33	40	73
2022 June	42	36	78
2022 May	40	71	111
2022 April	48	43	91
2022 March	45	65	110
2022 February	29	22	51
2022 January	49	39	88
2021 December	42	46	88
2021 November	59	57	116
2021 October	69	72	141
2021 September	69	40	109
2021 August	36	38	74
2021 July	44	40	84
2021 June	51	51	102
2021 May	49	44	93
2021 April	118	110	228
2021 March	53	24	77
2021 February	42	24	66
2021 January	38	26	64
2020 December	34	20	54
2020 November	30	23	53
2020 October	31	18	49
2020 September	26	34	60
2020 August	24	22	46
2020 July	25	19	44
2020 June	38	24	62
2020 May	33	23	56
2020 April	28	20	48
2020 March	13	7	20
2020 February	1	0	1
2018 May	6	1	7
2018 April	50	10	60
2018 March	136	11	147
2018 February	30	3	33
2018 January	29	12	41
2017 December	38	13	51
2017 November	49	15	64
2017 October	50	11	61
2017 September	42	12	54
2017 August	32	9	41
2017 July	42	10	52
2017 June	65	12	77
2017 May	59	23	82
2017 April	58	21	79
2017 March	37	15	52
2017 February	33	6	39
2017 January	28	11	39
2016 December	70	18	88
2016 November	52	16	68
2016 October	101	11	112
2016 September	102	12	114
2016 August	65	12	77
2016 July	38	9	47
2015 December	3	0	3
2015 November	1	13	14
2015 October	1	23	24
2015 September	2	0	2
2015 August	2	26	28
2015 July	33	12	45
2015 June	70	20	90
2015 May	100	47	147

Show all

Indexed in:

Follow us:

Subscribe:

Statistics

Indexed in:

Follow us:

Subscribe:

Statistics

Subscribe to our newsletter